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Epidermolytic hyperkeratosis (bullous congenital ichthyosi-
form erythroderma) is an autosomal dominant skin disorder 
caused by defects in the suprabasal keratins. Recently, muta-
tions in the keratins 1 and 10 have been identified in patients 
with this disease. In this study, direct gene sequencing was 
used to establish the prenatal diagnosis in 1S-week gestation 
twins at risk for epidermolytic hyperkeratosis. Direct se-
quence analysis of genomic DNA from the affected father 
and from both chorionic villus samples revealed a tyrosine to 
asparagine mutation at position 14 within the highly con-
E pidermolytic hyperkeratosis (EHK) is an autosomal dominant genodermatosis (number 11380 in McKusick [1 J ) manifested by erythroderma and widespread blis-tering at birth and the development of hyperkeratosis in later weeks [2J. Blistering is less common in older indi-
viduals but superficial erosions can occur after physical trauma, 
stress, or in some patients, on treatment with retinoids . Histopa-
thology is characterized by a marked expansion of the granular and 
stratum corneum layers. Analysis of blistering skin shows cytolysis 
and intra-epidermal cleavage in the suprabasallayers [3]. The ultra-
structural hallmark of EHK is the appearance of keratin filament 
aggregates and clumping, often with a pe:inuclear distribution , in 
the spinous and granular cells of these patIents [4,5]. In fact, ultra-
structural studies were the first to suggest an association between the 
disease and defects in the suprabasal keratins [4 - 6J and this view was 
later reinforced by immunochemical [7] and gene linkage [8 - to] 
studies. Recently, we and others have described mutations in highly 
conserved regions of keratins 1 and 10 (K1 and K10) in patients 
with this di sease [11-14] . All defects documented in EHK patients 
to date have involved point mutations resulting in amino acid sub-
stitutions within the HI segment of K 1 or within the specialized 
sequences at the ends of the rod domains of Kl and K10 . These 
conserved regions are critical to normal filament function and as-
sembly, and mutations in them are thought to weaken the integrity 
of these filaments, leading to collapse of the network and tonofila-
ment clumping around the nucleus (reviewed in [15] . Interestingly, 
most of these mutations occur within a conserved sequence motif at 
the beginning of the rod domain of Kl 0, with the arginine codon at 
position 10 being particularly vulnerable to mutation [14] . 
Prenatal diagnosis of EHK has been performed previously by 
ultrastructural analysis of fetal skin biopsies and on amn.iotic fluid 
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served lA alpha-helical segment of keratin 10. None of the 
unaffected family members that were analyzed exhibit this 
mutation nor have polymorphic variations been observed in 
the normal population at this position. This residue is invar-
iant in all type I keratins sequenced to date and is also con-
served in related intermediate fil ament proteins such as vi-
men tin and lamin. Given this high degree of conservation it 
is probable that any mutation at this position is deleterious 
and will result in disease. Key wo rds: keratins/ mutatiol1s/dis-
ease/genetics. ] Invest Dennatol1 02:13 -16, 1994 
cells [1 6- 19]. The diagnosis is based on tbe finding of keratin 
filament aggregates in these ce lls. However, analysis of amniotic 
cells is not considered rel iable enough to exclude the possibili ty of a 
false-negative diagnosis and ultrastructural analysis of fetal skin 
biopsies requires the sampling of more than one site, because tonofi-
lament clumping may not be uniformly presented throughout the 
fetal epidermis [20]. Although in the normal fe tus keratinization 
does not begin until the twenty-fourth week, the sugrabasal keratins 
Kl and KI0 are expressed as early as week 14 [21], giving this 
gestational age as the absolute lower limit for a diagnosis based on 
ultrastructure analysis. However, the earliest gestational age re-
ported for a prenatal diagnosis of EHK is 19 weeks [20]. Here we 
report the prenatal diagnosis of twin fetuses at risk for EHK using 
direct gene sequencing of chorionic villus samples at 15 weeks ges-
tation. In addition, the genetic defect causing EHK in this fami ly is 
described. 
MATERIALS AND METHODS 
Extraction of Nucleic Acids D NA was extracted from 10 ml of whole 
blood by lysing cellmembrancs in an equal volume of 10 mM Tris-HC I (pH 
7.5),0.32 M sucrose,S 111M MgCl2 and 1 % Triton XlOO. Intact nuclei were 
collected by centrifugation and suspended in 1.5 ml 0.9% NaCI and 1.5 ml 
lysis buffer (Applied Biosystems, Foster City, CAl, and incubated with pro-
teinase K at a final concentration 0[250 Ilg/ml at 37"C for 16 h. DNA was 
extracted from chorionic villus samples by incubating approximately 20 mg 
of tissue in 200 III lys is buffer (10 mM Tris-HCI, pH 8.0, 2 rnM ethylenedia-
minte traacetic acid, 10 rnM NaCI, 5% sodiumdodecyl sulfate) and protein-
ase K toa linal concentration of250)1g/ml at 55 · C for 16 h. All DNAs were 
purified using phenol/chloroform extraction and isopropanol precipitation 
[22]. The extracted DNA was dissolved in 10 111M Tris (pH 7.4), 1 111M 
ethylenediamine tetraacetic ac id and stored at 4 · C. Concentration and pu-
rity were assessed by spectrophotometer. 
peR and Nucleotide Sequencing T he l A region ofKI0 was amplified 
from genomic DNA usin g specific oligonucleotides (5'-GAGGA-
GATGGTGGCCTTCTCTCTGG- 3' and 5'-GCATAGTGAACAGC-
CACATTGTGC-3') corresponding to bp 2080-2104 and to 2372-2395 
of the published sequence [23]. The 5' oligonucleotide was biotinylated to 
enable the purification of single stranded DNA for sequencing [24). The 
sequencing primer used was 5'-GTATTTGCTGTAGTCACG-3', corre-
sponding to bp 2253-2270 of the published sequence [23). The simulta-
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Figure 1. Pedigree of the EHK-M fami ly. Men are represented by squares, 
women by circles, and the fetuses by diamollds. Solid symbols denote affected 
individuals. 
neous amplification and sequencing of both the mutant and wild-type alleles 
enables the rapid identification of nucleotide changes in affected individuals. 
After peR amplification, the DNA was captured onto streptavidin-coated 
magnetic beads via the biotinylated primer and denatured, and the resultant 
single-stranded DNA was used as a template in a manual DNA sequencing 
reaction (11). 
RESULTS AND DISCUSSION 
The proband, a 32-year-old man with EHK, first approached us for 
a prenatal diagnosis during the thirteenth week of his wife's second 
pregnancy. The proband was born to unaffected non-consan-
guineous parents and is the only member of his family w ith a der-
matologic disorder (Fig 1). Diagnosis ofEHK was made at birth and 
later confirmed by ultrastructural analysis. 
By history, he suffered from extensive blistering as a neonate and 
development of erosions and inflammation with bacterial superin-
fection later as a child. Episodes of blistering gradually diminished 
with age but were replaced with widespread hyperkeratosis. He has 
responded well to retinoid treatment (etretinate 35 mg daily, orally) 
with a diminution of hyperkeratosis. External therapy consisted of 
10% urea pura ointment. The couple has had one previous preg-
nancy resulting in a healthy unaffected boy, now 6 years old (indi-
vidual IlI.1 in Fig 1). 
To provide a prenatal diagnosis, we first had to ascertain the 
genetic defect of the father. of the EHK patients that we have 
studied to date (total of12 probands) ([11,14] and unpublished data), 
nearly 50% bear mutations within the "helix initiation" motif of 
KI0, a further 25% bear mutations elsewhere in the rod domain of 
KIO or in Kl and in the other 25% of patients we have been unable 
to locate a mutation within the rod domains of these keratins. It is 
probable that these patients harbor mutations in one of the other 
suprabasal keratins such as K2e [25]. In our initial analysis we se-
quenced the regions in which all mutations causal for EHK have 
been documented including the Hl, lA, and 2B segments ofKl and 
the lA and 2B segments of both K1 and K10 from the proband. This 
analysis revealed a T to A transversion, resulting in a tyrosine (Y) to 
asparagine (N) substitution at position 14 of the K10 1A segment 
(Fig 2). No other substitutions were observed in either Kl or KIO. 
To ensure that this mutation was not the result of a spurious alter-
ation introduced by the polymerase chain reaction, each reaction 
was repeated and the products sequenced independently. Unaf-
fected family members did not exhibit this base change in their 
DNA (Fig 3). Moreover, we have observed no sequence polymor-
phisms at this site in the DNA from 50 unrelated individuals, nor 
are there any reports of polymorphic variations of this residue in the 
literature. 
The first 15 residues of the 1A segment are highly conserved 
among all intermediate filament types [26] and are thought to be 
involved in filament assembly through interactions with the 
TYRXLLEGE motif at the end of the 2B segment of neighboring 
molecules [27]. The tyrosine to asparagine substitution at position 
14 of this highly conserved region is therefore likely to affect the 
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Figure 2. Sequence anal ysis of the 1 A segment of K 10 from the EH K-M 
proband (individual 11.2 in Fig 1). Normal, sequence obtained from an 
unaffected individual. Hetero, sequence obtained from the proband who is 
heterozygous for the mutant allele. The amino acid residues are numbered 
with respect to the beginning of the rod domain (11). The proband bears a 
T-A transversion that results in a tyrosine (Y) to asparagine (N) substitu-
tion at residue 14 of the rod doman. This position corresponds to residue 160 
in Rieger and Franke [23). 
stability of these head-to-tail interactions, producing a weakened 
filament that is prone to collapse. Although there is as yet no func-
tional data available, either from transgenic or tissue culture studies, 
confirming that this mutation is causal for this disease, the nature 
and position of the mutation suggests that it is so. This tyrosine is 
absolutely conserved in all human type 1 keratins sequenced to date 
as well as in keratins of other species and in the other intermediate 
filament proteins [12,26,28). The high degree of conservation of 
this residue suggests that few, if any, changes at this position can be 
tolerated. Thus any mutations are likely to be deleterious and lead to 
disease, and on this basis we felt confident to proceed with the 
prenatal diagnosis. 
The chorionic villus DNA samples were subsequently analyzed 
and both were found to contain the same T to A transversion as the 
proband (Fig 3) and a diagnosis ofEHK was made. We were fortu-
nate that the proband's mutation occurred within a highly con-
served and well-characterized region of the gene. Had the proband's 
mutation occurred in a less-conserved region we would have been 
very circumspect in rendering a diagnosis in the absence of support-
ing functional data from in "itro and transgenic studies. As our data 
base increases for both mutations segregating with the disease, as 
well as polymorphic variation within the unaffected population, 
these determinations will be made with greater confidence. Al-
though this is the first report of this substitution in K10 or in any 
other type 1 keratin, a tyrosine-to-aspartate substitution has been 
described at this position in another EHK proband.§ 
§ Chipev CC, Yang J-M, Steinert PM, Compton JG: Mutations in the 
keratin 10 gene in patients with epidermolytic hyperkeratosis.] II/vest Der-
mato1100:516, 1993 (abstr). 
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Figure 3. Direct genomic sequencing of the tA region ofKl 0 of unaffected fami ly members and both chorionic villus samples. Note that both fetuses (III.2, 
111 .3) are heterozygous for the mutant allele at position 14 of the rod domain. 
The autosomal dominant mode of inheritance of EHK, coupled 
with its virtually complete penetrance [14], permits prenatal diag-
nosis once the exact defect has been identified in the affected patent. 
In this case chorionic vi llus samples were analyzed at 15 weeks but 
the technique would work equally as well at a gestational age as 
early as 8 weeks. Furthermore, the direct gene sequencing protocol 
can be used to screen ill vitro fertilized embryos, from affected cou-
ples, prior to implantation [29]. Once screened, unaffected embryos 
can be selected for transfer to the uterus, thereby eliminating the 
need for risky surgical procedures for prenatal diagnosis later in the 
pregnancy or for the need to terminate an affected fetus. 
Note Added ill Proof The prenatal diagnosis of EHK has since been 
confirmed by ultrastructural analysis of epidermal biopsies taken at 
18 weeks gestational age (Dr. M. Megahed, Department of Derma-
tology, University of Dusseldorf, personal communication). 
We tl.allk Drs. E. Sc lr rader alld C. Ral.rbonr (Illstilllte oj HI/lila 11 Cetletics, UlIi-
versify oJDiisseidorj) Jor tl.e prepara!ioll oJpatiellt DNA samples. We tlrallk Drs. M. 
Levy {/lid A .M. Dominey (Department oj Dermatology, Ba),lor) Jor illsiglriflll com-
ments, alld NJ. Lamillack Jar tl.e preparatioll oj tire matH/script. Tlris IVork IVas 
supported by a NIH gra lll (HD25479) to DRR. 
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FIRST ANNOUNCEMENT 
International Symposium on Inherited Epidermolysis Bullosa will be held April 25 - 26, 1994, 
sponsored by the Department of Dermatology and The Office of Continuing Medical Educa-
tion, University of North Carolina School of Medicine and The National Epidermolysis Bul-
losa Registry (NEBR) . 
An intensive two day meeting is planned which will include lectures and panel discussions by 
leading authorities in the field. A poster session will also be held. Clinical topics include 
subclassification of EB phenotypes, demographic and epidemiologic findings from the NEBR 
and other cohorts, application of biostatistical modeling techniques as predictors of diagnosis 
and prognosis, carcinogenesis and EB, critical re-evaluation of laboratory diagnostic criteria, 
and multifaceted approaches to therapy. Basic research topics will include qualitative and 
morphometric ultrastructural changes within skin in selected EB phenotypes, altered antige-
nicity as a marker of disease, the role of enzymes in the pathogenesis ofEB, and a mini-sympo-
sium on the molecular biology of EB. 
For more detailed information and registration and abstract forms, contact Jo-David Fine, 
M.D., M.P.H., Department of Dermatology, The University of North Carolina at Chapel 
Hill, 137 NCMH, CB# 7600, Chapel Hill, NC 27514, (919) 966-3321, FAX (919) 966-3921. 
